NASDAQ · CNSPHealthcarePharmaceuticals

CNS Pharmaceuticals news

$4.91−3.97%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About CNS Pharmaceuticals

No recent articles focused on CNS Pharmaceuticals.

Also mentions CNSP

Articles that tag CNSP but are mainly about other companies.

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight

GlobeNewswire Inc.May 27, 1:00 PM ET▲ Positive

Berubicin is in Phase 3 development for recurrent GBM with early efficacy signals, and Berzosertib advanced Phase 3 trial in November 2025.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology